Discover and read the best of Twitter Threads about #COAPT
Most recents (5)
#COAPT Risk Score for Death or #HeartFailure 🏥
📍Simple risk score using 4 clinical (COPD, #NYHA class, Afib/Aflut, and #CKD)
📍4 #EchoFirst (#LVEF, LVESD, RVSP, and #TR) variables + 1 treatment-related variable (#TEER)
jacc.org/doi/10.1016/j.… @JACCJournals @GreggWStone
📍Simple risk score using 4 clinical (COPD, #NYHA class, Afib/Aflut, and #CKD)
📍4 #EchoFirst (#LVEF, LVESD, RVSP, and #TR) variables + 1 treatment-related variable (#TEER)
jacc.org/doi/10.1016/j.… @JACCJournals @GreggWStone
Using data from the #COAPT trial, a simple risk score using 4 clinical and 4 Echo parameters + 1 treatment-related variable (#TEER), which provides prognostic insight into the 2-year rates of ☠️ or #HeartFailure 🏥 in patients with symptomatic #HF and severe #FMR
@JACCJournals
@JACCJournals
There was consistent benefit from TEER with MitraClip across all risk strata
FMR and HF pts are at ⬆️ risk for ☠️ and recurrent HFH, despite best Med Rx & invasive Tx including MV TEER
👉🏻Future studies are needed to externally validate the COAPT risk score in pts with HF & FMR
FMR and HF pts are at ⬆️ risk for ☠️ and recurrent HFH, despite best Med Rx & invasive Tx including MV TEER
👉🏻Future studies are needed to externally validate the COAPT risk score in pts with HF & FMR
What are your pearls for assessing the mechanism & severity of #mitralregurgitation by #EchoFirst?
#JACCIMG presents an imaging-based curriculum to review functional #mitralvalve regurgitation for #CardioTwitter.
Follow/share this #Tweetorial! (1/15) bit.ly/3gw5MZ2
#JACCIMG presents an imaging-based curriculum to review functional #mitralvalve regurgitation for #CardioTwitter.
Follow/share this #Tweetorial! (1/15) bit.ly/3gw5MZ2
JACCIMG #Tweetorial (3/15)
Shown is an example of flail leaflet of the #mitralvalve at the P2 segment.
Surgical #mitralvalve repair is the gold standard; due to prohibitive risk, the patient underwent successful percutaneous repair #TMVR, guided by 3D #EchoFirst.
Shown is an example of flail leaflet of the #mitralvalve at the P2 segment.
Surgical #mitralvalve repair is the gold standard; due to prohibitive risk, the patient underwent successful percutaneous repair #TMVR, guided by 3D #EchoFirst.
@ACCinTouch @AHAScience @JACCJournals @CircAHA 2020 VHD guidelines. Here's a series of tweet-synopsis. First: #TAVR and AS. Key wasn't just Figure 3 but Table 14 where it highlights specifics favoring SAVR vs TAVR. To me it's informative. @AATSHQ @STS_CTsurgery @EACTS @escardio
#2: Bicuspid AV: recommendations on management of ascending aorta and root @NimeshDesaiMD @OPreventzaMD @OuzounianMD @EricRoselliMD @AortaSurg @DrZeigler1 @AATSHQ @STS_CTsurgery @ACCinTouch @AHAScience @JACCJournals @CircAHA
#3: Primary MR: TEER (E2E repair) #MitraClip is now Class 2A in high or prohibitive pts with "favorable" anatomy. Asymptomatic but LV dysfn DMR is Class 1 for surgery if repair possible @GAilawadiMD @DrMoritzWvB @TsuyoshiKaneko1 @AATSHQ @STS_CTsurgery @ACCinTouch @AHAScience
#ACC19 #LBCT
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
@PCRonline
1PANACHE: Safety:Efficacy of Neladenoson Bialanate, Partial Adenosine A1 Receptor Agonist, in CHF & Preserved EF: PANACHE RCT
2PIONEER-HF: Initiation of Angiotensin-Neprilysin Inhibition after Acute Decomp CHF: Open-Label Extension of
PIONEER-HF Trial
3 Hopeful Heart Trial: Blended Collaborative Care for Treating ❤️Failure & Comorbid Depression: 12-Month Outcomes
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
4 CODIACS-QoL: Randomized Trial of Depression Screening After ACS: Comparison of Depression Identification After ACS-QOL & Cost Effectiveness
(THREAD)
By @rwyeh request, I bring you this brief introduction of joint frailty models and their application in the #COAPT trial...
By @rwyeh request, I bring you this brief introduction of joint frailty models and their application in the #COAPT trial...
Please be advised that @graemeleehickey and others are more expert than I am in the direct, real-world application of such models, but here I am, so whatever. Read it, or don’t.
Suppose you’re just reading along in the #COAPT primary paper, found here:
nejm.org/doi/full/10.10…
when you encounter this bumfuzzle:
nejm.org/doi/full/10.10…
when you encounter this bumfuzzle:
